Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease | Zendy

L Wagner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease

Author(s) -

L Wagner

Publication year - 2005

Publication title -

core evidence

Language(s) - English

Resource type - Journals

eISSN - 1555-175X

pISSN - 1555-1741

DOI - 10.2147/ce.s6404

Subject(s) - roflumilast , medicine , copd , tolerability , intensive care medicine , exacerbation , placebo , clinical trial , adverse effect , pathology , alternative medicine

Chronic obstructive pulmonary disease (COPD), characterized by a progressive deterioration of lung function caused primarily by the inhalation of toxic substances, is a leading cause of morbidity and mortality worldwide. Current treatment options for the management of its symptoms include the use of bronchodilators and glucocorticoid agents that are not universally beneficial and which are associated with limitations. Phosphodiesterase-4 (PDE4) inhibitors are a novel class of antiinflammatory agents being developed for COPD treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research